Abstract
OBJECTIVE: To propose a conceptual model to identify points along the condition course where actions or inaction affect downstream burdens of non–cancerous genitourinary conditions (NCGUC). MATERIALS AND METHODS: The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) convened an interdisciplinary meeting to comprehensively consider the burdens of NCGUCs. Subsequently, the authors met monthly to conceptualize the model. RESULTS: Inflection points (IP) describe time points during a condition course that are sensitive to change. Our proposed Inflection Point Model (IPM) helps conceptualize burden/benefit trade-offs in any related decision and provides a platform to identify the downstream aggregate burden of a NCGUC across multiple socio-ecological levels at a single time point, which may be summed across the condition course to measure cumulative burden. Two personae demonstrate the utility of this model to better understand impacts of 2 common NCGUCs. CONCLUSION: The IPM may be applied in multiple contexts: narrowly to explore burden of a single NCGUC at a single IP; or more broadly, to address multiple conditions, multiple IPs, or multiple domains/levels of social ecology. Applying the IPM may entail combining population data describing prevalence of NCGUCs, associated behaviors, and resulting outcome patterns that can be combined with suitable mathematical models to quantify aggregate and cumulative burden. The IPM challenges stakeholders to expand from the individual to include broader levels of social ecology. Application of the IPM will undoubtedly identify data gaps and research needs that must be fulfilled to delineate and address the burden of NCGUCs.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 56-65 |
| Number of pages | 10 |
| Journal | Urology |
| Volume | 166 |
| DOIs | |
| State | Published - Aug 2022 |
| Externally published | Yes |
Bibliographical note
Funding Information:The authors dedicate this manuscript in memory of Michelle Lynn McGarry (1965-2020), who contributed to early iterations of the conceptual model presented in this manuscript. The authors acknowledge the contributions of Nicole Zhang, PhD, RN, Tamara Bavendam, MD, MS, Christine Liu, MD, W Stuart Reynolds, MD, MPH, Karen Rose, MD, and Mary Worstell, MPH who helped develop the personas featured in this manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views or policies of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institutes of Health (NIH), or the U.S. Environmental Protection Agency (EPA). Any mention of trade names, products, or services does not imply an endorsement by the U.S. Government, NIDDK, NIH or the EPA. The U.S. Government does not endorse any commercial products, services, or enterprises. There are no reported financial or personal relationships that could bias this work. Financial and Personal Disclosures: Jenna M. Norton: None; Annemarie Dowling-Castronovo: None; Britt Conroy: None; Adonis K. Hijaz: Collamedix Inc (equity) and Astellas (speaker); Michelle Kim: None; Christine N. Loizou: None; David E Meyer: None; Melissa L. Constantine: None
Publisher Copyright:
© 2021
PubMed: MeSH publication types
- Journal Article
